Staffs hospitals with travel nurses, physicians and allied health professionals, plus workforce-scheduling software.
Staffs hospitals with travel nurses, physicians and allied health professionals, plus workforce-scheduling software.
Bills hospitals an hourly rate for each clinician placed and pays the clinician less, so results depend on how many contract shifts hospitals buy and on the gap between the two rates. Nurse staffing carries the company, with physician placement next. Its software lets a hospital run several outside staffing agencies from one system.
Moat: narrow (scale, installed base). Large clinician networks and hospital VMS contracts give an edge over smaller staffing rivals.
Headquarters: Dallas, Texas, US · Founded: 1985 · Employees: 2,664
Size AMN Healthcare Services (AMN) is a United States Health Care company (Personnel Services) with a market value of $1.45B, the 1991st largest of 3,085 United States companies the cockpit tracks. Shares closed at $37.60 on 18 Nov 2026.
Performance Over six months the shares gained 40.0%, against -5.9% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 29.4% over the last twelve months (peer median +13.0%); the operating margin is 5.8% (peer median -3.5%).
Valuation It trades at 40.8× forward earnings against a peer median of 13.5× (most expensive of 9).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.9 points above its cost of capital (6.6% WACC).
Short interest Short interest is 11.1% of the free float (30 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.52B | $2.73B | $2.98B | $3.79B | $5.24B |
| Revenue growth | — | -8% | -21% | -28% | — |
| Gross profit | $870M | $626M | $752M | $1.09B | $1.58B |
| EBITDA | $342M | $190M | $294M | $502M | $781M |
| Net income | $109M | -$95.7M | -$147M | $211M | $444M |
| Free cash flow | $327M | $234M | $240M | $268M | $578M |
| Capital expenditure | $34.0M | $35.6M | $80.9M | $105M | $80.9M |
| Total debt | $775M | $803M | $1.10B | $1.35B | $861M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.7% | -9.2% | 11th highest of 21 |
| 6-month return | +40.0% | -5.9% | 4th highest of 21 |
| Distance from 52-week high | -24.2% | -41.1% | 4th highest of 21 |
| Revenue growth (TTM) | +29.4% | +13.0% | 6th highest of 18 |
| Operating margin | 5.8% | -3.5% | 6th highest of 19 |
| Forward P/E | 40.8× | 13.5× | most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | -10.6% | 7.4% | least demanding of 8 |
| Growth delivered (Del g) | +2.7% | +18.3% | lowest of 8 |
| Hurdle (Req g minus delivered) | -13.3 pp | -20.5 pp | 3rd most demanding of 8 |
| ROIC minus cost of capital | +5.9 pp | -12.7 pp | 4th highest of 13 |
| EV / EBITDA | 5.7× | 12.4× | 2nd cheapest of 8 |
| Net debt / EBITDA | 1.5× | 2.1× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AMN Healthcare Services AMN | United States | $1.45B | +40% | +29% | 6% | 40.8× | -10.6% | +2.7% |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% | +12.7% |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 16.7× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | n/a | n/a | n/a |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| Astrana Health ASTH | United States | $1.47B | -24% | +35% | 3% | 17.6× | 7.4% | +35.9% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | n/a | n/a | n/a |
| Alignment Healthcare ALHC | United States | $1.41B | -60% | +36% | 1% | n/a | 12.2% | +32.7% |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 4.9× | 0.5% | +25.6% |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | n/a | n/a | n/a |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |